SAN DIEGO, Sept. 20, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a number one supplier of autoimmune testing options, introduced in the present day the acceptance of 9 abstracts at the 2022 American College of Rheumatology’s (ACR) annual assembly, ACR Convergence 2022, being held November 10-14, 2022, at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.
Selected as a Featured Poster and ACR’s Ignite Talk is “Targeted Synovial Tissue RNA-Seq Coupled with Artificial Intelligence Accurately Predicts Early Rheumatoid Arthritis Patients Likely to Respond to csDMARDs, Enriching csDMARDs Response Rates and Enabling Early Identification of Patients Requiring Subsequent Biological Therapy,” half of the core know-how powering Exagen’s AVISE® RADR take a look at improvement. In addition, knowledge from Exagen’s analysis on machine studying in sufferers with fibromyalgia has been accepted for an oral presentation.
Exagen’s President and Chief Executive Officer, Ron Rocca, shared, “Exagen is honored to have nine scientific abstracts accepted for ACR’s 2022 annual conference, with a featured poster focusing on AVISE® RADR and a podium presentation. We continue to assist physicians by adding clarity to their clinical diagnoses by providing precision testing; we believe good science leads to good decisions.”
Below is the record of accepted abstracts, with hyperlinks to every:
Saturday, November 12, 2022
Poster Presentation | Presented by Geoffrey Stephens, PhD | Abstract #0324
Title: Comparison of nCounter® and BioFire® Technologies for the Measurement of Type I Interferon Signature
Session Title: SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis
Session Time: 1:00 – 3:00pm ET
Sunday, November 13, 2022
Featured Poster Presentation | Presented by Giorgio Casaburi, PhD | Abstract #0935
Title: Targeted Synovial Tissue RNA-Seq Coupled with Artificial Intelligence Accurately Predicts Early Rheumatoid Arthritis Patients Likely to Respond to csDMARDs, Enriching csDMARDs Response Rates and Enabling Early Identification of Patients Requiring Subsequent Biological Therapy
Session Title: RA – Treatment Poster II
Session Time: 9:00 – 10:30am ET
Poster Presentation | Presented by Anca Askanase, MD | Abstract #1442
Title: Role of Platelet-bound Complement Activation Product (PC4d) in Predicting Risk of Future Thrombotic Events in Systemic Lupus Erythematosus
Session Title: SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations
Session Time: 1:00 – 3:00pm ET
Poster Presentation | Presented by Mark Rudolph, PhD | Abstract #1221
Title: Multi-Center Validation of Cell-Bound Complement Activation Products and a Multianalyte Assay Panel Distinguishing Systemic Lupus Erythematosus from Primary Fibromyalgia
Session Title: Fibromyalgia and Other Clinical Pain Syndromes Poster
Session Time: 1:00 – 3:00pm ET
Poster Presentation | Presented by Emily G Oaks | Abstract #1201
Title: Autoimmune Serologies, Cell-Bound Complement Activation Products, and Autoimmune Rheumatic Disease Symptoms after COVID-19 Infection
Session Title: Epidemiology and Public Health Poster II
Session Time: 1:00 – 3:00pm ET
Monday, November 14, 2022
Poster Presentation | Presented by Mark Rudolph, PhD | Abstract #1762
Title: Stability of Cell Bound Complement Activation Products (CB-CAPS), Multianalyte Assay Panel (MAP) with Algorithm, and Other Autoimmune Biomarkers Among Clinical Patients Throughout the SARS-COV-2 Pandemic and Vaccination Campaigns
Session Title: Epidemiology and Public Health Poster III
Session Time: 1:00 – 3:00pm ET
Poster Presentation | Presented by Giorgio Casaburi, PhD | Abstract #1990
Title: Artificial Intelligence Applied to Transcriptomics Profiling of Synovial Tissue Biopsies Accurately Predicts Rheumatoid Arthritis Patients who will Respond or be Refractory to Standard Biological Treatments
Session Title: RA – Treatment Poster IV
Session Time: 1:00 – 3:00pm ET
Poster Presentation | Presented by Jennifer Rogers, MD | Abstract #2104
Title: The Use of Cell-bound Complement Activation Product to Assess Disease Activity in SLE.
Session Title: SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes
Session Time: 1:00 – 3:00pm ET
Oral Presentation | Presented by Geoffrey Stephens, PhD | Abstract #2233
Title: Machine Learning Uncovers Novel mRNAs Expressed in Fibromyalgia
Session Title: Abstracts: Fibromyalgia and Other Clinical Pain Syndromes
Session Time: 4:30 – 5:30pm ET
About Exagen Inc.
Exagen (Nasdaq: XGN) is a number one supplier of autoimmune diagnostic, prognostic, and monitoring testing options. Exagen is a affected person centered, discovery pushed group constructed on the success of AVISE® testing and is investing in its product pipeline to assist sufferers all through their autoimmune prognosis and therapy journeys. The objective at Exagen is to help sufferers, physicians, and payors by enabling precision drugs. Exagen is situated in San Diego County with scientific and analysis and improvement laboratories in Vista, CA.
For extra info, please go to Exagen.com and comply with @ExagenInc on Twitter.
Forward Looking Statements
Exagen cautions you that statements contained on this press launch relating to issues that aren’t historic information are forward-looking statements. These statements are primarily based on Exagen’s present beliefs and expectations. Such forward-looking statements embody, however are usually not restricted to, statements relating to our scientific analysis and improvement staff’s scientific abstracts for presentation at ACR Annual Conference and the potential to result in elevated adoption of any AVISE® take a look at. The inclusion of forward-looking statements shouldn’t be considered a illustration by Exagen that any of its plans might be achieved. Actual outcomes might differ from these set forth on this press launch as a result of dangers and uncertainties inherent in Exagen’s business, together with, with out limitation: the COVID-19 pandemic might proceed to adversely have an effect on its business, monetary situation and outcomes of operations, together with because of this of slowdown in its operations in addition to these of its suppliers and courier companies, impeding affected person motion and interruptions to healthcare companies inflicting a lower in take a look at volumes, disruptions to the provision chain of materials wanted for its exams inflicting a rise in price per take a look at, its gross sales and commercialization actions and its means to obtain specimens and carry out or ship the outcomes from its exams, delays in reimbursement and protection choices from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and deliberate scientific trials involving its exams; Exagen’s business success relies upon upon attaining and sustaining vital market acceptance of its testing merchandise and promoted therapeutics amongst rheumatologists, sufferers, third-party payors and others within the medical group; Exagen’s means to efficiently execute on its business methods; third-party payors not offering protection and ample reimbursement for Exagen’s testing merchandise or promoted therapeutics, together with Exagen’s means to gather funds due; expectations relating to its pipeline merchandise, together with the event of the AVISE® RADR platform; Exagen’s means to acquire and keep mental property safety for its testing merchandise; regulatory developments affecting Exagen’s business; and different dangers described in Exagen’s prior press releases and Exagen’s filings with the Securities and Exchange Commission (“SEC”), together with underneath the heading “Risk Factors” in Exagen’s Annual Report on Form 10-Ok for the yr ended December 31, 2021 and any subsequent filings with the SEC. You are cautioned to not place undue reliance on these forward-looking statements, which communicate solely as of the date hereof, and Exagen undertakes no obligation to replace such statements to mirror occasions that happen or circumstances that exist after the date hereof. All forward-looking statements are certified of their entirety by this cautionary assertion, which is made underneath the secure harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investor Relations
Exagen Inc.
Ryan Douglas
[email protected]
760.560.1525
Company
Exagen Inc.
Kamal Adawi, Chief Financial Officer
[email protected]
760.477.5514
